ClinicalTrials.gg
Enrolling by invitationNCT07142759ViTaL-DUpdated Aug 27, 2025

Investigating the Impact of Vitamin D Biofortified Tomatoes on Serum Levels of 25(OH)D

An interventional study of Precision Bred Provitamin D-rich Tomato Soup and Precision Bred Vitamin D-rich Tomato Soup in Vitamin D Insufficiency, sponsored by Quadram Institute Bioscience. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Quadram Institute Bioscience · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In the UK, vitamin D deficiency occurs frequently especially during the winter months. Vitamin D biofortified tomatoes have been developed using precision breeding technique by researchers at John Innes Centre. Biofortification uses crop breeding to increase the nutritional value of crops. The goal of the ViTaL-D study is to examine whether the vitamin D biofortified tomatoes when eaten as a soup can increase blood levels of vitamin D in men and women with vitamin D deficiency. Additionally, researchers will learn if the tomato soups are feasible and safe to eat everyday. The main questions the study aims to answer are:

  • Does vitamin D biofortified tomatoes increase vitamin D levels in men and women with low blood levels of vitamin D?
  • Is consuming vitamin D biofortified tomatoes safe and easy to eat everyday as a soup?

Researchers will compare how four types of tomato soup increase blood vitamin D levels. The four types of soup are:

  • Soup with vitamin D biofortified tomatoes
  • Soup with provitamin D biofortified tomatoes
  • Soup with store-bought tomatoes not containing vitamin D
  • Soup with store-bought tomatoes with added vitamin D

Participants will:

  • Eat one of the four types of tomato soup every day for 21 days.
  • Visit the clinic once every 7 days after a 12 hour fast for body measurements, tests, and surveys.
  • Keep a daily diary when soups are eaten and when time is spent outside.
Read the detailed description

The ViTaL-D study is a 21-day randomized, double-blind, placebo-controlled four-arm parallel pilot study conducted at the NIHR (National Institute for Health and Care Research) Norfolk Clinical Research Facility (CRF) in the Quadram Institute in Norwich. Researchers are seeking adult (at least 18 years and older) men and women who have serum 25-hydroxyvitamin D (25[OH]D) levels between 25-40 nmol/L to determine whether soups made with precision bred, biofortified vitamin D tomatoes will increase vitamin D levels. There are a total of 6 study visits (1 consent visit, 1 screening visit, and 4 short visits). At these visits, anthropometric measurements and vital signs will be collected. Participants will be asked to complete questionnaires (food frequency, international physical activity, and sensory evaluation). They will record their daily consumption of soup as well as their daily sun exposure and wear a UV tracker when they are outdoors.

Researchers will measure fasting blood samples for serum 25[OH]D, serum electrolytes, calcium, phosphorous, parathyroid hormone, cholesterol, triglycerides, plasma lycopene, plasma beta carotene, and bone turnover biomarkers. Participants will be given the choice to donate optional samples of saliva and/or 24 hour urine collection. For these optional samples, researchers will quantify vitamin D metabolites (7-DHC, 1,25(OH)2D, 24,25(OH)2D, and C-3 epi 25(OH)D) in saliva and urine as well as vitamin D binding protein in saliva.

Participants will consume one of four soups everyday for 21-days. The four soups are described as such:

  • Soup with precision bred tomatoes biofortified with provitamin D (7-dehydrocholesterol-rich, No UV-Treatment). This soup is made with precision bred tomatoes. Tomatoes have been engineered to accumulate 7-dehydrocholesterol (7-DHC, also called provitamin D, a precursor of vitamin D3). The bioefficacy of the provitamin D in the diet is largely unknown.
  • Soup with precision bred tomatoes (Vitamin D-rich, UV-Treated) This soup is made with the same precision bred tomatoes, but in this case, the tomatoes have been treated with ultraviolet (UV) light to convert the accumulated 7-DHC into vitamin D3. UV exposure mimics the natural process by which human skin synthesizes vitamin D3 from sunlight.
  • Soup with store bought tomatoes (placebo). In this soup, store bought conventional tomatoes contain negligible amounts of 7-DHC and no vitamin D3. This soup is the placebo soup.
  • Soup with store bought tomatoes supplemented with Vitamin D3. In this soup, same store-bought tomatoes will be supplemented with vitamin D (from lanolin).
02

Conditions studied

  • Vitamin D Insufficiency

Keywords

  • tomato soup
  • precision breeding
  • biofortification
  • vitamin D
  • 25-hydroxy vitamin D (25[OH]D)
  • dietary intervention
03

In context

Lead sponsor

Quadram Institute Bioscience is the lead sponsor of 44 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be willing to eat a tomato soup daily for 21 days.
  • Have access to a smartphone or tablet device and internet access.
  • Be at least 18 years old
  • Be able to understand the study and provide
  • Have serum 25-hydroxyvitamin D (25[OH]D) levels between 25-40 nmol/L
  • 18.5 to 35 kg/m2
  • Live within 40 miles of the Quadram Institute.

Exclusion criteria

Exclusion Criteria:

  • Have a known allergy or intolerance to tomatoes or to any of the soup components (tomatoes, milk, wheat, lanolin are the major allergens, but a detailed list is in Annex 16) of the test soups.
  • Currently undergoing treatment or on medications for hypo/hypercalcaemia, hypo/hyperparathyroidism, kidney stones, or bone diseases.
  • Have anaemia, or viral infections that may compromise immunity. This will be assessed on a case-by-case basis by QI medical advisor.
  • Have any acute or chronic illnesses that affects the outcome of the study such as a gastrointestinal disorder. This will be assessed on a case-by-case basis by Quadram Institute medical advisor.
  • Have just started taking or changed dose of vitamin D supplement in the month prior to the start of the intervention or at any point during the intervention, or are regularly taking more than 400 International Units (IU) of vitamin D.
  • Are on a routine regimen of vitamin D supplementation over 400 IU who have begun supplementation or had changes in their dose a month prior or have changes during the course of the study.
  • Are on any medication regimen that may alter vitamin D absorption they are as follow but not limited to; bile acid sequestrants, hormone replacement therapy, thiazides, calcium channel blockers, isoniazid, anti-seizure medications, and antacids.
  • Any dietary restriction that prevents the consumption of the study soups or follow a diet programme which requires fasting for multiple days (soups are not suitable for vegans).
  • Have abnormally low or high blood pressure (i.e. ≤90/60, ≥160/100).
  • Plan to become pregnant during the study duration, pregnant or breastfeeding.
  • Are currently taking part in an intervention study.
  • Are a registered blood donor and have donated a large quantity of blood within the last 6 weeks. Registered blood donors should abstain from blood donations for the duration of the study.
  • Are unable to give written or verbal
  • Unable to provide your GP contact details.
  • Fall under the line management structure or live in the same household with any of the research team, or the QIB Human Studies Team
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Soup with Precision Bred Tomatoes (Provitamin D-rich, No UV-Treatment)

    Soup made with precision bred (gene-edited) tomatoes that have been engineered to accumulate 7-dehydrocholesterol (7-DHC) also known as provitamin D is a precursor of vitamin D3. These tomatoes have undergone CRISPR-Cas9 gene editing to allow the accumulation of 7-DHC in the tomatoes and remains to be rich in 7-DHC when protected from UV light.

    Other: Precision Bred Provitamin D-rich Tomato Soup

  • Experimental
    Soup with Precision Bred Tomatoes (Vitamin D-rich, UV-Treated)

    Soup is made with the same precision bred tomatoes, but in this case, the tomatoes have been treated with ultraviolet (UV) light to convert the accumulated 7-DHC into vitamin D3. UV exposure mimics the natural process by which human skin synthesizes vitamin D3 from sunlight.

    Other: Precision Bred Vitamin D-rich Tomato Soup

  • Placebo comparator
    Soup Made with Wild-Type (Store-bought) Tomatoes

    In this soup, store-bought (wild-type) tomatoes contain negligible amounts of 7-DHC and no vitamin D3.

    Other: Wild-type (store-bought) Tomato Soup

  • Active comparator
    Soup Made with Wild-Type (Store-bought) Tomatoes with Vitamin D3 Supplement

    In this soup, store-bought (wild-type) tomatoes are used and supplemented with vitamin D3 (lanolin).

    Other: Wild-type (store-bought) Tomato with vitamin D supplementation Soup

Interventions

  • OtherPrecision Bred Provitamin D-rich Tomato Soup

    Participants will consume one tomato soup every day for 21 days as part of their normal diet.

  • OtherPrecision Bred Vitamin D-rich Tomato Soup

    Participants will consume one tomato soup everyday for 21-days as part of their normal diet.

  • OtherWild-type (store-bought) Tomato Soup

    Participants will consume one tomato soup every day for 21 days as part of their normal diet.

  • OtherWild-type (store-bought) Tomato with vitamin D supplementation Soup

    Participants will consume one tomato soup everyday for 21 days as part of their normal diet.

06

What researchers measure

Primary outcomes

  1. Change in plasma lycopene and beta carotene to assess adherence

    Fasting plasma total carotenoids and total lycopene

    Time frame: Day 0 and Day 21

  2. Differences in soup acceptability using sensory evaluation questionnaires as a measure of adherence

    Soup acceptability will be measured using a 9-point hedonic scale and 5 point Just-about-Right scale

    Time frame: Screening visit (Day -60 to -1), Day 1, and Day 21

  3. Assess changes in eating pattern due to daily consumption of soup

    VioScreen Food frequency questionnaire

    Time frame: Day 0 and Day 21

  4. Changes in serum 25-hydroxy vitamin D (25(OH)D) to monitor safety

    Fasting serum 25(OH)D levels

    Time frame: Day 0 and Day 21

  5. Changes in serum electrolytes, calcium and phosphorous to monitor safety

    Fasting serum electrolytes, calcium and phosphorus

    Time frame: Day 0 and Day 21

  6. Change in parathyroid hormone to assess safety

    Fasting plasma parathyroid hormone

    Time frame: Day 0 and Day 21

  7. Assess change in bone turnover biomarkers on serum 25(OH)D levels

    Fasting serum procollagen Type 1 N-Terminal Propeptide and Collagen Type 1 Cross-Linked C Telopeptide (P1NP and CTx)

    Time frame: Day 0 and Day 21

  8. Measure changes in sunlight exposure

    Quantify sunlight exposure using Outdoor Skin Assessment, Sun-a-Wear UV tracker UV (duration UV exposure and UV Index)

    Time frame: Day 0 and Day 21

  9. Measure changes in physical activity

    Physical activity will be measured using the International Physical Activity Questionnaire - short version

    Time frame: Day 0 and Day 21

Secondary outcomes

  1. Treatment effects of daily tomato soup consumption on vitamin D3 or its precursor (7-DHC) on serum 25(OH)D, PTH, cholesterol

    Fasting serum 25(OH)D levels Fasting plasma PTH Fasting serum cholesterol, triglycerides, and 25(OH)D levels

    Time frame: Day 21

  2. Quantify differences in vitamin D metabolites

    Vitamin D metabolites measured in serum and urine are provitamin (7-DHC), 1,25(OH)2D, 24,25(OH)2D, and C-3 epi 25(OH)D)

    Time frame: Day 0 and Day 21

  3. Changes in the quantity of vitamin D and their binding proteins in saliva

    Vitamin D metabolites (provitamin (7-DHC), 1,25(OH)2D, 24,25(OH)2D, and C-3 epi 25(OH)D) will be measured in non-stimulated and stimulated saliva Vitamin D binding protein will be measured in non-stimulated and stimulated saliva

    Time frame: Day 0 and Day 21

  4. Correlate salivary vitamin D and salivary vitamin D binding protein and serum 25(OH)D levels

    Vitamin D metabolites (provitamin (7-DHC), 1,25(OH)2D, 24,25(OH)2D, and C-3 epi 25(OH)D) in non-stimulated and stimulated saliva collection Fasting serum 25(OH)D

    Time frame: Day 0 and Day 21

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — Individual participant data which complies with General Data Protection Regulations will be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Apr 2027, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 27, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Mar 31, 2028
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07142759
Lead sponsor
Quadram Institute Bioscience
Collaborators
University of Surrey, John Innes Centre, Norfolk and Norwich University Hospitals NHS Foundation Trust, NIHR Norfolk Clinical Research Facility
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Aug 27, 2025

Study contacts

Martin Warren, PhD
principal investigator · Quadram Institute Bioscience

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion